Drug Combo Proves Powerful Against Lung Cancer Hopewell Junction NY

A two-drug combination treatment in Hopewell Junction proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

RICHARD DIAMOND, MD
(845) 534-3888
164 Willow Avenue
Cornwall, NY
MICHAEL MARESCA, MD
(845) 454-1942
19 Baker Avenue
Poughkeepsie, NY
EMIL WASSEF, MD
(914) 962-5151
352 Downing Drive
Yorktown Heights, NY
Alfred Joseph Cretella, MD
860-354-5511
11 Grove St
New Milford, CT
Robert L McKee, MD
914-896-6203
7 Fair Oaks Dr
Poughkeepsie, NY
Javier A Ruiz, MD
(845) 561-4450
59 New Windsor Hwy Rte 32
New Windsor, NY
ANUP DAS, MD
(845) 278-7966
664 Stoneleigh Avenue
Carmel, NY
FAUZIA PARACHA, MD
(845) 562-6240
327 Fullerton Avenue
Newburgh, NY
Niloufer A Rodrigues, MD
845-454-1942
1 Webster Ave Ste 502
Poughkeepsie, NY
Malcolm G Idelson, MD
845-462-3444
11 Carnelli Ct
Poughkeepsie, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Side Effect Of Chemotherapy Drugs Hopewell Junction NY
Lung cancer remains the biggest cancer killer, projected to claim 163,510 lives this year. Paclitaxel will be used in the attempt to save the lives of many of these patients. However, one little-known effect of Paclitaxel is that in a subset of these patients there will be up to a fivefold increase in the production of Interleukin. Read on and learn more.
- Genetic Clues for Skin Cancer Therapies Hopewell Junction NY
- Delayed Prostate Cancer Therapy Hopewell Junction NY
- Exercise for Breast Cancer Survival Hopewell Junction NY
- Hormone Therapy for Breast Cancer Hopewell Junction NY
- Risks for Childhood Cancer Survivors Hopewell Junction NY
- Exercise for Prostate Cancer Hopewell Junction NY
- Hormone Therapy for Lung Cancer Hopewell Junction NY
- Fungal Infection Treatments Hopewell Junction NY